Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
59.46
+0.20 (0.34%)
Mar 9, 2026, 4:06 PM GMT
Arrowhead Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Equivalents | 71.37 | 88.71 | 76.21 | 110.89 | 108.01 | 184.43 |
Short-Term Investments | 714.97 | 692.82 | 578.28 | 292.74 | 268.39 | 183.36 |
Cash & Short-Term Investments | 786.34 | 781.52 | 654.48 | 403.63 | 376.4 | 367.79 |
Cash Growth | 42.21% | 19.41% | 62.15% | 7.23% | 2.34% | 16.58% |
Accounts Receivable | 218.87 | 6.82 | - | - | 1.41 | 10.26 |
Other Current Assets | 169.18 | 162.29 | 40.99 | 12.85 | 27.49 | 6.55 |
Total Current Assets | 1,174 | 950.64 | 695.47 | 416.47 | 405.3 | 384.6 |
Net Property, Plant & Equipment | 421.95 | 426.41 | 431.56 | 335.56 | 168.59 | 66.02 |
Other Intangible Assets | 6.44 | 6.86 | 2.56 | 10.26 | 11.96 | 13.66 |
Long-Term Investments | - | - | - | - | 105.87 | 245.6 |
Other Long-Term Assets | 1.41 | 1.39 | 4.48 | 3.26 | 0.22 | 0.27 |
Total Assets | 1,604 | 1,385 | 1,140 | 765.55 | 691.94 | 710.15 |
Accounts Payable | 32.94 | 17.67 | 11.39 | 35.87 | 2.87 | 9.46 |
Accrued Expenses | 144.35 | 117.31 | 85.01 | 57.73 | 59.11 | 23.77 |
Short-Term Debt | 40 | 40 | - | - | - | - |
Current Portion of Leases | 7.53 | 7.29 | 6.34 | 10.56 | 2.78 | 2.25 |
Unearned Revenue | 111.93 | 2.4 | - | 0.87 | 74.1 | 111.06 |
Other Current Liabilities | 10.68 | 10.81 | 0.43 | 0.44 | - | - |
Total Current Liabilities | 347.43 | 195.49 | 103.17 | 105.46 | 138.85 | 146.54 |
Long-Term Debt | 538.11 | 582.28 | 734.54 | 268.33 | - | - |
Long-Term Leases | 102.13 | 104.11 | 111.03 | 104.61 | 78.8 | 23.3 |
Other Long-Term Liabilities | 53.83 | - | - | - | 55.95 | 131.5 |
Total Long-Term Liabilities | 694.06 | 686.39 | 845.57 | 372.93 | 134.75 | 154.79 |
Total Liabilities | 1,041 | 881.88 | 948.74 | 478.39 | 273.6 | 301.33 |
Common Stock | 0.23 | 0.23 | 0.22 | 0.2 | 0.2 | 0.2 |
Treasury Stock | -53.19 | -53.19 | - | - | - | - |
Additional Paid-in Capital | 2,211 | 2,140 | 1,806 | 1,300 | 1,219 | 1,053 |
Accumulated Other Comprehensive Income | 6.7 | 6.44 | 2 | -3.22 | -0.14 | -0.07 |
Retained Earnings | -1,596 | -1,627 | -1,626 | -1,026 | -820.76 | -644.69 |
Total Common Shareholders' Equity | 568.42 | 466.05 | 182.69 | 271.34 | 398.52 | 408.82 |
Minority Interest | -5.73 | 37.36 | 8.37 | 15.82 | 19.82 | - |
Shareholders' Equity | 562.7 | 503.42 | 191.06 | 287.16 | 418.34 | 408.82 |
Total Liabilities & Equity | 1,604 | 1,385 | 1,140 | 765.55 | 691.94 | 710.15 |
Total Debt | 687.76 | 733.68 | 851.91 | 383.5 | 81.58 | 25.55 |
Net Cash (Debt) | 98.57 | 47.84 | -197.43 | 20.13 | 294.82 | 342.24 |
Net Cash Growth | 106.04% | - | - | -93.17% | -13.86% | 16.27% |
Net Cash Per Share | 0.72 | 0.36 | -1.65 | 0.19 | 2.80 | 3.30 |
Book Value | 568.42 | 466.05 | 182.69 | 271.34 | 398.52 | 408.82 |
Book Value Per Share | 4.14 | 3.48 | 1.53 | 2.54 | 3.78 | 3.94 |
Tangible Book Value | 561.99 | 459.19 | 180.13 | 261.08 | 386.56 | 395.16 |
Tangible Book Value Per Share | 4.09 | 3.43 | 1.50 | 2.45 | 3.67 | 3.81 |
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.